Table 1.
Characteristics of the analysis sample (n = 1170)
| Quartile of tIS |
|||||
|---|---|---|---|---|---|
| Overall | <23 μg/mL | 23–32 μg/mL | 32–42 μg/mL | 42+ μg/mL | |
| IS, range, μg/mL | 0–102 | 0–23 | 23–32 | 32–42 | 42–102 |
| IS, mean (SD), μg/mL | 33.1 (15.4) | 15.2 (5.6) | 27.3 (2.6) | 36.3 (3.0) | 53.8 (10.5) |
| IS, median (IQR), μg/mL | 31.6 (22.6, 42.0) | 16.5 (11.8, 19.7) | 27.1 (25.2, 29.5) | 36.0 (33.7, 39.1) | 50.6 (45.9, 58.4) |
| Age, mean (SD), years | 65.6 (12.2) | 66.1 (12.5) | 65.7 (11.6) | 66 (12.5) | 64.4 (12.2) |
| Vintage, median (IQR), years | 6.1 (2.8, 12.5) | 3.5 (1.5, 8.5) | 5.9 (3.0, 13.2) | 6.6 (3.1, 12.6) | 7.6 (4.2, 15.0) |
| RKF, % | 16.1 | 22.6 | 16.4 | 15.4 | 9.9 |
| Primary end-stage renal disease cause, % | |||||
| Diabetes | 34.8 | 42.1 | 33.3 | 34.2 | 29.5 |
| Glomerulonephritis | 38.1 | 34.5 | 37.9 | 38.9 | 41.1 |
| Hypertension | 7.1 | 6.5 | 8.5 | 6.2 | 7.3 |
| Other | 20.0 | 16.9 | 20.2 | 20.7 | 22.2 |
| Male, % | 62.6 | 63.4 | 59.0 | 64.5 | 63.4 |
| HDF use, % | 8.2 | 8.2 | 7.5 | 7.8 | 9.2 |
| Vascular access, % | |||||
| Arteriovenous fistula | 93.1 | 93.7 | 93.9 | 93.6 | 91.2 |
| Arteriovenous graft | 6.5 | 5.6 | 5.4 | 6.4 | 8.4 |
| Central venous catheter | 0.4 | 0.7 | 0.7 | 0.0 | 0.4 |
| Single-pool Kt/V urea, mean (SD) | 1.42 (0.29) | 1.35 (0.33) | 1.42 (0.29) | 1.43 (0.28) | 1.46 (0.25) |
| BMI, mean (SD), kg/m2 | 21.5 (3.6) | 21.7 (3.8) | 21.3 (3.7) | 21.4 (3.5) | 21.4 (3.5) |
| nPCR, mean (SD) | 0.93 (0.20) | 0.89 (0.20) | 0.93 (0.20) | 0.94 (0.19) | 0.97 (0.18) |
| CVD at study entry, % | 42.8 | 44.2 | 43.3 | 46.8 | 37.0 |
| Cancer (nonskin) at study entry, % | 10.4 | 12.3 | 7.2 | 9.2 | 13.0 |
| Cerebrovascular disease at study entry, % | 12.0 | 11.0 | 14.3 | 11.9 | 10.6 |
| Diabetes at study entry, % | 37.2 | 46.6 | 36.5 | 33.8 | 31.8 |
| GI bleeding at study entry, % | 4.5 | 3.4 | 3.4 | 4.8 | 6.5 |
| Hypertension at study entry, % | 80.7 | 82.5 | 82.6 | 83.6 | 74.0 |
| Lung disease at study entry, % | 3.3 | 2.4 | 3.4 | 3.1 | 4.5 |
| Neuro disorder at study entry, % | 6.2 | 8.2 | 5.8 | 5.1 | 5.5 |
| Psych disorder at study entry, % | 4.8 | 4.5 | 4.1 | 4.8 | 5.8 |
| Peripheral vascular disease at study entry, % | 14.3 | 11.6 | 16.0 | 11.6 | 17.8 |
| Recurrent cellulitis at study entry, % | 2.8 | 1.0 | 3.8 | 3.8 | 2.7 |
| Albumin, mean (SD), g/dL | 3.7 (0.4) | 3.6 (0.4) | 3.6 (0.4) | 3.7 (0.3) | 3.8 (0.3) |
| Hemoglobin, mean (SD), g/dL | 10.6 (1.2) | 10.7 (1.2) | 10.5 (1.3) | 10.6 (1.2) | 10.7 (1.1) |
| Creatinine, mean (SD), mg/dL | 10.7 (2.8) | 9.5 (2.9) | 10.4 (2.7) | 11.2 (2.6) | 11.7 (2.6) |
| Calcium, mean (SD), mg/dL | 8.6 (0.7) | 8.6 (0.7) | 8.6 (0.7) | 8.7 (0.7) | 8.6 (0.7) |
| Phosphorus, mean (SD), mg/dL | 5.1 (1.3) | 4.9 (1.2) | 4.9 (1.3) | 5.2 (1.3) | 5.3 (1.3) |
| Intact parathyroid hormone, median (IQR), pg/mL | 120 (62–216) | 108 (56–186) | 106 (60–197) | 140 (65–218) | 143 (75–259) |
| High-sens. C-reactive protein, median (IQR), mg/dL | 0.08 (0.03–0.27) | 0.10 (0.03–0.35) | 0.09 (0.03–0.30) | 0.08 (0.03–0.26) | 0.07 (0.03–0.20) |
Data are shown using first imputation only. GI, gastrointestinal.